Clinical Scorecard: The Blood-Brain Barrier: Beneficial Protector or Therapeutic Obstacle?
At a Glance
Category
Detail
Condition
Blood-brain barrier (BBB) function and dysfunction in neurological diseases
Key Mechanisms
Specialized endothelial cells with tight junctions form the BBB, regulating molecular transport and protecting the brain microenvironment; BBB restricts entry of most therapeutics
Target Population
Patients with neurological conditions including neurodegeneration, acute brain injuries, and ageing populations
Care Setting
Neurology, neurovascular, and neurodegenerative disease management settings
Key Highlights
BBB protects brain from toxins and pathogens but restricts >98% of small molecule and 100% of large molecule therapeutics.
BBB heterogeneity exists along arteriovenous axis and across brain regions, influencing transport and disease progression.
BBB breakdown and prolonged permeability are biomarkers of adverse outcomes in neurological injuries and neurodegeneration.
Guideline-Based Recommendations
Diagnosis
Assess BBB integrity as a biomarker in neurological injuries and neurodegenerative diseases.
Utilize molecular and imaging techniques to evaluate BBB heterogeneity and dysfunction.
Management
Consider challenges of BBB permeability in CNS drug development and therapeutic delivery.
Employ repetitive high-dose intravenous infusions for therapies with limited BBB penetration (e.g., anti-amyloid-β antibodies).
Explore novel drug delivery strategies targeting BBB transport mechanisms.
Monitoring & Follow-up
Monitor BBB permeability changes during disease progression and treatment response.
Use biomarkers of BBB breakdown to predict adverse neurological outcomes.
Risks
Limited therapeutic efficacy due to restricted BBB penetration of drugs.
Potential adverse outcomes associated with prolonged BBB permeability and breakdown.
Patient & Prescribing Data
Patients with Alzheimer's disease and other neurological conditions requiring CNS therapeutics
Anti-amyloid-β antibodies like aducanumab require high-dose, repetitive intravenous infusions due to <0.1% brain penetration; BBB limits effective drug delivery.
Clinical Best Practices
Recognize the BBB as both a protective barrier and a therapeutic obstacle in CNS disease management.
Incorporate understanding of BBB heterogeneity and molecular changes in treatment planning.
Leverage emerging molecular and spatial transcriptomic data to develop targeted BBB drug delivery systems.
Monitor BBB integrity as part of neurological disease diagnosis and prognosis.
